4//SEC Filing
Booth Bruce 4
Accession 0001451612-25-000012
CIK 0002036042other
Filed
Oct 20, 8:00 PM ET
Accepted
Oct 21, 5:12 PM ET
Size
21.7 KB
Accession
0001451612-25-000012
Insider Transaction Report
Form 4
Booth Bruce
Director
Transactions
- Sale
Common Stock
2025-10-21$32.69/sh−22,339$730,262→ 2,360,156 total(indirect: By Atlas Venture Fund XI, L.P.) - Sale
Common Stock
2025-10-21$33.87/sh−4,187$141,814→ 693,110 total(indirect: By Atlas Venture Opportunity Fund II, L.P.) - Sale
Common Stock
2025-10-21$35.69/sh−5,316$189,728→ 686,584 total(indirect: By Atlas Venture Opportunity Fund II, L.P.) - Sale
Common Stock
2025-10-21$34.91/sh−1,210$42,241→ 691,900 total(indirect: By Atlas Venture Opportunity Fund II, L.P.) - Sale
Common Stock
2025-10-21$34.91/sh−5,763$201,186→ 2,334,445 total(indirect: By Atlas Venture Fund XI, L.P.) - Sale
Common Stock
2025-10-21$35.69/sh−25,327$903,921→ 2,309,118 total(indirect: By Atlas Venture Fund XI, L.P.) - Sale
Common Stock
2025-10-21$36.42/sh−17$619→ 686,567 total(indirect: By Atlas Venture Opportunity Fund II, L.P.) - Sale
Common Stock
2025-10-21$32.69/sh−4,688$153,251→ 697,297 total(indirect: By Atlas Venture Opportunity Fund II, L.P.) - Sale
Common Stock
2025-10-21$33.87/sh−19,948$675,639→ 2,340,208 total(indirect: By Atlas Venture Fund XI, L.P.) - Sale
Common Stock
2025-10-21$36.42/sh−83$3,023→ 2,309,035 total(indirect: By Atlas Venture Fund XI, L.P.)
Footnotes (8)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on February 25, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.19 to $33.057 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (6), (7) and (8).
- [F3]These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI "). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims beneficial ownership of such securities held by AVF XI, except to the extent of his pecuniary interest therein, if any.
- [F4]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on February 25, 2025.
- [F5]These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.305 to $34.28 inclusive.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.30 to $35.29 inclusive.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.30 to $36.14 inclusive.
Documents
Issuer
Sionna Therapeutics, Inc.
CIK 0002036042
Entity typeother
Related Parties
1- filerCIK 0001451612
Filing Metadata
- Form type
- 4
- Filed
- Oct 20, 8:00 PM ET
- Accepted
- Oct 21, 5:12 PM ET
- Size
- 21.7 KB